The control of the rather slowly progressing disease B-cell chronic lymphocytic leukemia (B-CLL) by the immune system is not yet fully understood. 1 Several immunosuppressive mechanisms lead to the escape of B-CLL cells from immunosurveillance. CD4 þ CD25 high T regulatory cells (T regs ) are considered to be key immunomodulatory cells of the immune system. Recently, enhanced frequencies of T regs in B-CLL were reported by Beyer et al. 2 Tumor progression and increased numbers of T regs have also been described for gastrointestinal tumors. 3 The addition of CD4 þ CD25 high cells to mixed lymphocyte reactions resulted in a decreased antigen recognition by CD8 þ T cells, which clearly proved the potency of T regs to suppress the T-cell response. 2 The forkhead family transcription factor FOXP3 is critically involved in the development and function of T regs . 4 In this study, we investigated the expression of FOXP3 in CD4 þ cells of the peripheral blood from patients with B-CLL.
Thalidomide (THAL) has been shown to inhibit the production of tumor necrosis factor (TNF), and several groups have reported a clinical benefit in patients treated with THAL and THAL analogues, suggesting an effective induction of an anti-tumor effect. 5 The addition of fludarabine (FLU) to the regimen has been reported to constitute an effective treatment for naive CLL patients. 5 However, the mechanism of action is still not well defined. In this study, we evaluated the influence of THAL alone as well as in combination with FLU on the T reg population to test the hypothesis that an effective treatment with these cytostatic drugs might not only reduce the malignant B-CLL cells, but also diminish the number of T regs .
Samples were taken from 60 previously untreated B-CLL patients admitted to the department of hematooncology at the Medical University of Lublin. Thirty patients were classified as stage A, 17 in B and 13 in C according to Binet classification (mean age: 63 years). The effect of THAL alone as well as in combination with FLU on the number of circulating T regs was evaluated in 15 B-CLL patients treated with the regimen proposed firstly by Chanan-Khan et al. 5 Patients received THAL at daily dose 100 mg p.o. starting from day 0 (D0). FLU was added for five consecutive days every 28 days, starting from day 7 (D7) i.v. at dose 25 mg/m 2 , for up to six cycles. Samples were collected on D0, D7 and D12 to evaluate the effect of THAL alone and in combination with FLU, respectively. The peripheral blood samples were also taken from the 10 healthy volunteers (HVs; age range: 25 -75 years, mean: 56 years; six male and four female). Informed consent was obtained from all patients and HVs with respect to the use of their blood for scientific purposes.
Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll density gradient centrifugation and stored in liquid nitrogen for fluorescence-activated cell sorting analysis. PBMCs from B-CLL patients were thawed with RPMI 1640 containing DNase (Sigma-Aldrich, Munich, Germany) with a yield of 495% viable cells. Next, cells were washed twice in phosphate-buffered saline containing 2% fetal calf serum (Biochrom AG, Berlin, Germany) and counted. The staining of the surface antigens CD4, CD8 and, CD25 was performed after incubation of 1 Â 10 6 cells with antibodies according to the manufacturer's protocol (BD Biosciences, Mannheim, Germany). Thereafter, cells were permeabilized, blocked with rat serum and stained with anti-FOXP3 rat monoclonal antibody according to the manufacturer's protocol (eBioscienes, San Diego, CA, USA). After intracellular staining, cells were washed twice and analyzed for the expression of FOXP3 and CD25 on CD4 þ cells by flow cytometry. A minimum of 100 000 cells were collected and analyzed. The number of CD4 þ
CD25
high FOXP3 þ cells was assessed and the percentage of T regs among CD4 þ T cells was calculated. All results were presented as mean values 7s.d. The U-Mann-Whitney test was used to evaluate differences between analyzed subgroups of patients and HVs. In 20 B-CLL patients, the TNF level in the serum was determined by human TNF-alpha Quantikine HS ELISA (R&D Systems, Minneapolis, Minnesota, USA) according to the manufacturer's protocol. Linear regression was used to assess correlation between age, lymphocytes count, TNF serum levels and the frequency of T regs .
In B-CLL patients, we identified a sub-population of CD4 þ CD25 high FOXP3 þ T cells, that is cells with the characteristic phenotype of T regs . The frequency of T regs was significantly higher in B-CLL patients when compared to HVs (12.1 vs 1.9%, P ¼ 0.001). A progressive increase of T regs was noted in advanced stages of the disease: mean 9.5% in stage A, 13.3% in stage B and 15.4% in stage C according to the Binet classification ( Figure 1) .
No correlation between the percentage of T regs and the ZAP-70 status was observed. Interestingly, a trend to higher frequencies in ZAP-70-negative patients was noted with 12.9 vs 11%, respectively (P ¼ 0.46). There was a tendency to higher percentages of T regs in patients who were CD38 þ (11 vs 15.3% P ¼ 0.055). A weak correlation of the frequency of T regs and the lymphocyte count was noted (r 2 ¼ 0.079, P ¼ 0.029). No significant correlation between the age of the patients and the percentage of T regs was observed (r 2 ¼ 0.034, P ¼ 0.156). Higher frequencies of T regs were observed in CLL patients with higher TNF serum levels (r 2 ¼ 0.45, P ¼ 0.001, n ¼ 20). A specific reduction of T regs after therapy with THAL was observed in 80% (12/15) of the B-CLL patients ( Table 1 ). The mean reduction was higher in the sub-population of T regs when compared to the whole lymphocyte population (41.2 vs 19.9%, P ¼ 0.046).
A novel therapeutical approach for B-CLL is to target the environment by the use of THAL and THAL analogues. THAL and lenalidomide were found to be effective in the treatment of B-CLL patients. 5 We reported earlier on the clinical effectiveness of a therapy with THAL and FLU in naive as well as refractory/ relapsed B-CLL patients (ASH 2006, abstract no. 2108). In this study, a specific reduction of T regs after therapy with THAL was observed, indicating that strategies combining THAL with FLU are very promising. THAL might not only target the CLL cell population but also decrease the number of T regs , and thereby restore the CD8 þ T-cell function in treated patients. Laurenti et al. 6 compared the efficacy and toxicity of a therapy combining THAL with oral FLU and cyclophosphamide in heavily pretreated patients with progressive CLL, and monitored the effects of this treatment on the serum TNF level. None of the patients responded to the therapy. Laurenti et al. 6 concluded that ineffective treatment correlated with increasing levels of TNF observed during the therapy. In contrast, we observed increasing levels of TNF as well as of interleukin (IL Elevated levels of TNF were associated with progressive disease in patients with B-CLL and increased with the stage of the disease. 7 Here, a correlation of the percentage of T regs and TNF was observed, suggesting a stimulation of T regs by TNF. Hence, patients with an increased number of T regs and elevated levels of TNF displayed impaired responsiveness against tumor and viral antigens. In contrast, TNF was reported to downregulate the suppressive function of T regs . 8 Elevated TNF concentrations in the serum of patients have been measured in various pre-neoplastic and malignant diseases when compared with the serum and tissue levels of TNF measured in healthy individuals. The results of our study suggest that TNF is unable to block the suppressive activity of T regs in B-CLL patients. Anti-TNF treatment with infliximab of patients with rheumatoid Table 1 Specific reduction of T regs after therapy with thalidomide in B-CLL patients Patient no.
Change of lymphocytes and T regs after 7 days of THAL therapy
Abbreviations: B-CLL, B-cell chronic lymphocytic leukemia; THAL, thalidomide; T regs , T regulatory cells.
Letters to the Editor arthritis (RA) upregulated the function of T regs . 8 Here, we described a decrease of T regs in B-CLL patients treated with THAL whose therapeutical anti-TNF effect is known. The effects of TNF might be opposite in patients with RA and CLL, indicating that different mechanisms might be involved in the regulation of the T regs function.
In summary, we found a high frequency of T regs in B-CLL patients in this study. The percentage of FOXP3 þ T regs was augmented along with the stage of disease. A therapy combining THAL and FLU reduced the number of T regs . Interestingly, the treatment with THAL resulted in the strongest reduction of T regs when compared with the overall lymphocyte population.
Are surrogates of IGHV gene mutational status useful in B-cell chronic lymphocytic leukemia? The example of Septin-10 We read with interest the study by Bilban et al.,
1 which compared the gene expression profile (GEP) of two groups of B-cell chronic lymphocytic leukemia (CLL), selected for different lipoprotein lipase (LPL) mRNA levels. Several GEP studies have shown that LPL, an essential enzyme of lipid metabolism, is one of the genes most closely associated with unmutated (UM) immunoglobulin variable heavy chain (IGHV) genes in CLL. On these basis, LPL has been proposed as a novel predictor for overall survival and progression in CLL patients. 2 Among 111 genes differentially expressed by CLL with high or low LPL expression, Bilban et al.
1 documented that expression of Septin-10 (SEPT10) significantly correlates with both high LPL mRNA levels and UM IGHV gene status. The authors highlighted also the prognostic value of SEPT10 as a time-to-treatment predictor, with a significant earlier need for therapy occurring in patients with high SEPT10 mRNA levels. 1 We recently reported a comprehensive characterization of IGHV3-21-expressing CLL, a disease subset recognized as a specific poor prognosis category, given its clinical behavior mostly independent of IGHV gene mutation status. 3 In this respect, we and others have demonstrated that IGHV3-21 CLL, although frequently displaying a mutated (M) IGHV gene configuration, has an overall survival similar to poor-prognosis UM CLL. [3] [4] [5] Consistently, GEP studies performed by our group and comparison of IGHV3-21 CLL versus non-IGHV3-21 CLL have identified a restricted number of genes (122 probes corresponding to 115 genes) whose differential expression may explain, at least in part, the clinical aggressiveness of IGHV3-21 CLL. 3 By reviewing the list of the 122 probes differentially expressed by IGHV3-21 CLL, 1 we found SEPT10 among the 62 probes (59 genes) significantly downregulated in this CLL subset.
3 Downregulation of SEPT10 in IGHV3-21 CLL was an unexpected finding, because SEPT10 expression is considered a poor prognostic marker and IGHV3-21 CLL typically has poor clinical outcome.
To investigate this issue in detail, a quantitative real-time PCR (QRT-PCR) procedure was specifically devoted to investigate the expression levels of SEPT10 in highly purified CLL cells from a series of IGHV3-21 (10 cases) and non-IGHV3-21 (19 cases) CLL, with either UM (14 cases) or M (15 cases) IGHV gene configuration (Figure 1a) . Briefly, 50 ng of retro-transcribed DNAse I-treated total RNA was amplified in the presence of 0.5 pmol/ml of primers specific for SEPT10 (sense: 5 0 -GCT AAG GTC AAC GCT GCA AT-3 0 ; antisense: 5 0 -TTT CTC CTT TAC TCG CTG CAC-3 0 ) or b2-microglobulin (b2M), 5 with the following protocol: 10 min at 951C for initial denaturation, 40 cycles of 15 s at 951C, 30 s at 571C (621C for b2M) and 1 min at 721C, followed by final extension at 721C for 5 min. Incorporation of SYBR Green dye into PCR products was monitored in real time with an ABI PRISM 7700 sequence
